Publications by authors named "Yuri Yagami"
Introduction: The Glasgow prognostic score (GPS) is an inflammation-related score based on C-reactive protein and albumin concentrations. Few studies have assessed the correlation between the GPS and the efficacy of chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Therefore, this study aimed to evaluate the utility of the GPS in predicting the survival outcomes of patients with ES-SCLC.
View Article and Find Full Text PDFIntroduction: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. Information regarding the association between the GPS and EGFR-TKI treatment effectiveness is limited; hence, we investigated whether the GPS can predict the response of NSCLC to EGFR-TKIs.
View Article and Find Full Text PDFArticle Synopsis
- - The prognosis for patients with peritoneal carcinomatosis from lung cancer is generally poor, but specific gene alterations like the BRAF V600E mutation can make them responsive to targeted therapies.
- - A 67-year-old Japanese male with stage IA3 lung adenocarcinoma developed peritoneal carcinomatosis after surgery and was treated with dabrafenib and trametinib, showing a positive clinical response and good tolerance to the therapy.
- - This case underscores the necessity of genetic testing in lung cancer patients for personalized treatment options that can improve outcomes, especially when facing complications like peritoneal carcinomatosis.
Article Synopsis
- The study explored the Glasgow prognostic score (GPS) as a potential predictor for the effectiveness of immune checkpoint inhibitor (ICI) treatment in non-small cell lung cancer (NSCLC) patients who previously received therapy.
- After reviewing 80 patients treated with pembrolizumab or atezolizumab, the results indicated that higher BMI and a GPS of 0 were associated with significantly longer progression-free survival (PFS) and overall survival (OS).
- The findings suggest that GPS can independently predict PFS and OS, highlighting its importance in assessing treatment outcomes in NSCLC patients on second or later-line ICI therapy.